4th International Patient & Physician Summit on Waldenström's Macroglobulinemia

Abstracts

Session 1

Pathological Diagnosis of WM  Roger Owen
Clinical Features of Waldenstrom's Macroglobulinemia  Marvin Stone
Laboratory Workup of the Patient with WM  Robert Kyle
Workup of the WM patient with Amyloidosis  Giampaolo Merlini
Can WM ISS be used to make treatment decisions?  Pierre Morel (Irene Ghobrial Presenting)

Session 2

Is IgM MGUS Always a Precursor to WM? Robert Kyle
Epidemiological Studies in Waldenström’s Macroglobulinemia Predisposition  Ola Landgren
Familial predisposition to WM: studies of WM susceptibility in high-risk families Mary McMaster
Associated Malignancies in WM patients Enrica Morra

Session 4

Indications for Treatment Robert Kyle
Response Assessment and Challenges Roger Owen
Bendamustine plus Rituximab versus CHOP plus Rituximab as First-Line-Treatment in Patients with Indolent Lymphomas and WM  Mathias Rummel

Session 5

Phase II Trial of single agent panobinostat (LBH589) in Relapsed or Relapsed/Refractory WM Irene Ghobrial
Primary Therapy of WM with Bortezomib and Rituximab  Irene Ghobrial
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with WM who respond to a rituximab containing regimen Leukothea Ioakimidis
Clinical characteristics and treatment outcome of disease related peripheral neuropathy in WM Patricia Sheehy
High-dose Therapy and Stem Cell Transplantation (SCT) in WM  Charalampia Kyriakou

The Bing Center

Bing Center for Waldenstrom's

Dana-Farber Cancer Institute

Harvard Medical School

Administrative Contact

Christopher Patterson

cpatterson1@partners.org

Tel: (617)632-6285

 

 

Mailing Address

Dana-Farber Cancer Institute

450 Brookline Avenue

Mayer-548

Boston, MA 02215